Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 13Myelodysplastic Syndromes 8Leukemia, Myelomonocytic, Chronic 6Triple Negative Breast Neoplasms 2Systemic Mastocytosis With an Associated Hematologic Neoplasm 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Neuroendocrine Tumors 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Leukemia, Biphenotypic, Acute 1Hodgkin Disease 1GATA2 Deficiency 1Central Nervous System Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1BRCA1 Mutation 1

Interventions

Cyclophosphamide 8Vincristine 6romidepsin 5Prednisone 5Doxorubicin 5Lenalidomide 4Etoposide 4fludarabine phosphate 3fludarabine 3Rituximab 3Dexamethasone 3Bortezomib 3Azacitidine 3selinexor 2darinaparsin 2carfilzomib 2belinostat 2Oxaliplatin 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Injections 2Gemcitabine 2Depsipeptides 2Dasatinib 2Carboplatin 2Brentuximab Vedotin 2Biopsy 2Bendamustine Hydrochloride 2Alemtuzumab 2umbralisib 1thymoglobulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, T-Cell, Peripheral × decitabine and cedazuridine drug combination × Clear all
NCT05403450 2026-02-23

A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)

Taiho Oncology, Inc.

Phase 1 Active not recruiting
33 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡